Thread by @StephenVLiu

#WCLC20 Highly anticipated results of oral TKI mobocertinib (TAK-788) in #EGFRex20 mutant NSCLC after prior platinum based chemotherapy. Huge unmet need and as @Jbauml reported at this meeting, likely underdiagnosed. #LCSM @IASLC @OncoAlert

#WCLC20 Cohort being discussed here is #EGFR exon 20 insertion NSCLC after prior platinum therapy and the EXCLAIM extension cohort. Many patients also had prior TKI therapy and prior immunotherapy. @IASLC

#WCLC20 Here are the topline results. RR 23-26% by IRC, RR 32-35% by investigator, DOR by IRC was 17.5m (!) and mPFS 7.3m -- for #EGFRex20, no clear standard. Mobocertinib certainly has some activity here. #LCSM

#WCLC20 Almost all patients had some reduction (waterfall left). Durability (for a subset) illustrated by the swimmer's on the right. #LCSM

#WCLC20 Similar results across subsets. Notable toxicity (G3+ TRAE 41-46%) - though only 10-17% AEs leading to discontinuation. G3+ diarrhea in 16-21%. QOL improvement reassuring. #LCSM

#WCLC20 Mobocertinib (TAK-788) has activity in #EGFRex20 NSCLC with RR ~ 26% after chemotherapy with a mPFS of 7.3m. While not as impressive as TKIs for EGFR sensitizing mutations, this remains a major need and could be an option for some patients. #LCSM @IASLC